Scarica l'app Stockscreener
53.36
3.23%
-1.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GPCR Giù?
Forum
Previsione
Precedente Chiudi:
$55.14
Aprire:
$54.98
Volume 24 ore:
736.85K
Relative Volume:
0.90
Capitalizzazione di mercato:
$3.79B
Reddito:
-
Utile/perdita netta:
$-170.73M
Rapporto P/E:
-19.82
EPS:
-2.6921
Flusso di cassa netto:
$-159.70M
1 W Prestazione:
-0.17%
1M Prestazione:
+28.49%
6M Prestazione:
-22.23%
1 anno Prestazione:
+182.33%
Intervallo 1D:
$52.45
$54.99
Intervallo di 1 settimana:
$52.45
$57.07
Portata 52W:
$15.80
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Nome
Structure Therapeutics Inc Adr
Settore
Industria
Telefono
(650) 457-1978
Indirizzo
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
53.36 | 3.79B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-05-02 | Iniziato | Citigroup | Buy |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-21 | Iniziato | JP Morgan | Overweight |
| 2024-04-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-07-27 | Iniziato | Piper Sandler | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2023-02-28 | Iniziato | BMO Capital Markets | Outperform |
| 2023-02-28 | Iniziato | Guggenheim | Buy |
| 2023-02-28 | Iniziato | Jefferies | Buy |
| 2023-02-28 | Iniziato | SVB Securities | Outperform |
Mostra tutto
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
NVO Rallies 11% in a Month: How Should Investors Play the Stock? - TradingView
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now? - TradingView
(GPCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
If You Invested $1,000 in Structure Therapeutics Inc ADR (GPCR) - Stock Titan
GPCRStructure Therapeutics Inc ADR Options - Finviz
Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock? - TradingView
Analysts Offer Insights on Technology Companies: Septerna, Inc. (SEPN) and Strategy (MSTR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims & Hers Health (HIMS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters? - TradingView
Form 4 Structure Therapeutics Inc ADR For: 29 June By Investing.com - Investing.com Nigeria
[Form 4] Structure Therapeutics Inc. Insider Trading Activity - Stock Titan
(GPCR) Risk Channels and Responsive Allocation - Stock Traders Daily
Structure Therapeutics, Inc. Sponsored ADR Actuals & Estimates (NASDAQ:GPCR) - TradingView
Form 144 Structure Therapeutics Inc. For: 25 June By Investing.com - Investing.com South Africa
[144] Structure Therapeutics Inc. SEC Filing - Stock Titan
Case Summary: Sangamo Therapeutics Chapter 11 - Bondoro
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching - AOL.com
Analysts Conflicted on These Healthcare Names: Phreesia (PHR) and Novo Nordisk (NVO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), Abbott Laboratories (ABT) and AbbVie (ABBV) - The Globe and Mail
Shareholders Approve Directors, Auditors at 2026 Meeting - The Globe and Mail
Director at Structure Therapeutics (NASDAQ: GPCR) gets 39,453 options - Stock Titan
Structure Therapeutics (GPCR) director receives 39,453 share options at $15 - Stock Titan
Structure Therapeutics (GPCR) grants 39,453-share option award to director - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) reports 2026 shareholder voting outcomes - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
(GPCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock? - TradingView
Why Structure Therapeutics’ Hot Obesity Stock Is Suddenly Sinking - TipRanks
Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA) - The Globe and Mail
H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Nuvalent (NUVL) and Viking Therapeutics (VKTX) - The Globe and Mail
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs? - TradingView
Why Structure Therapeutics Shares Are Suddenly Sinking - TipRanks
Structure Therapeutics Maintained at Buy as Analyst Highlights Best-in-Class Oral GLP-1 Profile and Keeps $145 Price Target Unchanged - TipRanks
3 potential takeover targets in obesity - Pharma Voice
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity - The Manila Times
Why Structure Therapeutics Stock Is Sliding Today - TipRanks
Zevra Therapeutics (NASDAQ: ZVRA) vote keeps classified board structure - Stock Titan
Oral obesity drug helped people lose up to 16% body weight in trial - Stock Titan
Can Eli Lilly's 2026 Acquisition Spree Diversify Growth Beyond GLP-1s? - TradingView
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues? - TradingView
Why Structure Therapeutics Stock Is Surging Higher - TipRanks
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), AngioDynamics (ANGO) - The Globe and Mail
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst? - TradingView
Analysts Offer Insights on Healthcare Companies: Agilent (A), Apogee Therapeutics (APGE) and Pfizer (PFE) - The Globe and Mail
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT) - The Globe and Mail
Hear Structure Therapeutics at Jefferies and Goldman Sachs healthcare talks - Stock Titan
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth? - TradingView
Structure Therapeutics Inc Adr Azioni (GPCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):